MedPath

Acupuncture for Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck Cancer

Not Applicable
Recruiting
Conditions
Radiotherapy; Complications
Malignant Tumor of Head and/or Neck
Interventions
Device: sham acupuncture
Device: verum acupuncture
Registration Number
NCT06272617
Lead Sponsor
West China Hospital
Brief Summary

A study on the efficacy and safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors

Detailed Description

The goal of this clinical trial is to investigate the efficacy and safety of acupuncture for oral-related complications in patients with head and neck malignant tumors who receive radiotherapy. The main questions it aims to answer are:

* the efficacy of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors

* the safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors

Participants will:

* be treated with real acupuncture or sham acupuncture

* be evaluated to learn the efficacy and safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors

Researchers will compare real acupuncture group with sham acupuncture group to see if acupuncture has good efficacy and safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
138
Inclusion Criteria
  • Patients diagnosed with malignant tumors of the head and neck without metastasis
  • Age ≥18, ≤80 years old
  • ZPS score ≤2
  • Receiving radiotherapy alone or concurrent radiotherapy with a radiation dose of >50 Gy, including at least one parotid gland
  • Judged to be able to receive acupuncture treatment, with all needle positions identified as accessible
  • Signed informed consent form
Exclusion Criteria
  • History of dry mouth, Sjogren's syndrome, or other underlying systemic condition known to cause dry mouth
  • Suspected or confirmed physical closure of both salivary gland ducts
  • Have a phobia of needles or prohibit the use of acupuncture at any acupuncture points
  • Have a history of head and neck radiotherapy
  • Have contraindications to acupuncture, including but not limited to bleeding disorders, having skin infections, ulcers or frequent infections
  • Have taken any medications or herbs within the past 30 days that may affect salivary function, plan to or eventually take such substances during the study period
  • Poor oral hygiene or severe periodontitis
  • Poor compliance
  • Other patients who, in the opinion of the investigator, are not suitable for participation in this study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
control groupsham acupuncturesham acupuncture
treatment groupverum acupunctureverum acupuncture
Primary Outcome Measures
NameTimeMethod
Xerostomia questionnaire scores1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment

Patients self-evaluated xerostomia according to Xerostomia questionnaire(score 0-100);Higher score indicates more severe symptoms

Secondary Outcome Measures
NameTimeMethod
Quality of Life assessed by EORTC QLQ-C301 week before radiotherapy;at the middle of treatment(3 weeks after the start of radiotherapy);at the end of treatment(the last radiation dose received, usually 6 or 6.5 weeks);1, 3, 6, 12 months after the end of treatment

Quality of Life is assessed by EORTC QLQ-C30(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire);transformed into 0-100 scales for different domains and symptoms;Higher domain scores represent better quality of life, while higher symptom scores represent worse quality of life

Changes of oral flora1 week before radiotherapy;at the middle of treatment(3 weeks after the start of radiotherapy);at the end of treatment(the last radiation dose received, usually 6 or 6.5 weeks);1, 3, 6, 12 months after the end of treatment

The changes of oral flora in patients' salivary or oral swab measured by 16s rDNA technique

Taste function assessed by electrogustometer test1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment

Assessed by electrogustometer test(score -6 to 34);Higher score indicates more severe symptoms

Neck Fibrosis1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment

Assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0 version:Fibrosis skin(grade 1-5);Higher grade indicates more severe symptoms

Salivary flow rate1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment

Researchers-measured unstimulated and stimulated salivary flow rates;Lower value indicates more severe symptoms

Taste function assessed by patients1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment

Assessed by Patients self-evaluated dysgeusia(score 19-95);Higher score indicates more severe symptoms

Quality of Life assessed by QLQ-H&N351 week before radiotherapy;at the middle of treatment(3 weeks after the start of radiotherapy);at the end of treatment(the last radiation dose received, usually 6 or 6.5 weeks);1, 3, 6, 12 months after the end of treatment

Quality of Life is assessed by QLQ-H\&N35(Head and neck cancer-related quality of life scale);transformed into 0-100 scales for different domains and symptoms;Higher scores represent worse quality of life

Tongue range of motion1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment

Assessed by Tongue Range of Motion Assessment Scale(score 0-100);Lower score indicates more severe symptoms

Taste function assessed by taste strips test1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment

Assessed by taste strips test(score 0-16);Lower score indicates more severe symptoms

Oral mucositis1 week before radiotherapy;twice a week during the treatment(usually every 3 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment

Oral mucositis is assessed by trained physicians according to World Health Organization (WHO) oral toxicity Scale(grade 1-5);Higher grade indicates more severe symptoms

Dysphagia1 week before radiotherapy;at the middle of treatment(3 weeks after the start of radiotherapy);at the end of treatment(the last radiation dose received, usually 6 or 6.5 weeks);1, 3, 6, 12 months after the end of treatment

Dysphagia is assessed by M.D.Anderson Dysphagia Inventory(score 20-100);Lower score indicates more severe symptoms

Adverse effectsup to 12 months

Assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0 version(grade 1-5);Higher grade indicates more severe symptoms

Trial Locations

Locations (1)

West China Hospital, Sichuan University

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath